Choong‐Hwan Kwak

Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers

Immune checkpoint inhibitors (ICIs), particularly antibodies targeting PD-1/PD-L1 and CTLA-4, have reshaped the treatment landscape of lung cancers, most notably non-small cell lung cancer (NSCLC). Nevertheless, only a subset of patients achieve durable benefit due to primary and acquired resistance that arises from tu...